Recent research have focused on the overlap of GLP|GIP|glucagon receptor stimulant therapies and DA neurotransmission. While GLP agonists are increasingly employed for treating type 2 T2DM, their unexpected consequences on reinforcement circuits, specifically influenced by dopaminergic systems, a